Anti-atherogenic effects of montelukast associated with reduced MCP-1 expression in a rabbit carotid balloon injury model.

[1]  Osamu Igawa,et al.  Role of cysteinyl leukotrienes in the proliferation and the migration of murine vascular smooth muscle cells in vivo and in vitro. , 2007, Cardiovascular research.

[2]  P. Söder,et al.  Increased leukotriene concentrations in gingival crevicular fluid from subjects with periodontal disease and atherosclerosis. , 2007, Atherosclerosis.

[3]  K. Kronmann,et al.  Statin therapy: not just used to lower cholesterol? , 2007, Critical care nursing quarterly.

[4]  M. Bennett,et al.  The Emerging Role of Vascular Smooth Muscle Cell Apoptosis in Atherosclerosis and Plaque Stability , 2007, American Journal of Nephrology.

[5]  B. Yeğen,et al.  Montelukast protects against renal ischemia/reperfusion injury in rats. , 2006, Pharmacological research.

[6]  Anders Gabrielsen,et al.  Expression of 5-lipoxygenase and leukotriene A4 hydrolase in human atherosclerotic lesions correlates with symptoms of plaque instability. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[7]  S. Dahlén,et al.  Treatment of asthma with antileukotrienes: first line or last resort therapy? , 2006, European journal of pharmacology.

[8]  B. Yeğen,et al.  Amelioration of sepsis-induced hepatic and ileal injury in rats by the leukotriene receptor blocker montelukast. , 2005, Prostaglandins, leukotrienes, and essential fatty acids.

[9]  P. Barter,et al.  Impact of Short-Term Administration of High-Density Lipoproteins and Atorvastatin on Atherosclerosis in Rabbits , 2005, Arteriosclerosis, thrombosis, and vascular biology.

[10]  E. Yeh,et al.  The pleiotropic effects of statins , 2005, Current opinion in cardiology.

[11]  T. Ichiyama,et al.  Cysteinyl leukotrienes induce monocyte chemoattractant protein 1 in human monocytes/macrophages , 2005, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[12]  F. Cipollone,et al.  Association Between 5-Lipoxygenase Expression and Plaque Instability in Humans , 2005, Arteriosclerosis, thrombosis, and vascular biology.

[13]  B. Yeğen,et al.  Leukotriene receptor blocker montelukast protects against burn-induced oxidative injury of the skin and remote organs. , 2005, Burns : journal of the International Society for Burn Injuries.

[14]  I. Charo,et al.  Chemokines in the pathogenesis of vascular disease. , 2004, Circulation research.

[15]  Jilly F. Evans,et al.  The 5-lipoxygenase pathway promotes pathogenesis of hyperlipidemia-dependent aortic aneurysm , 2004, Nature Medicine.

[16]  W. Boisvert.  Modulation of atherogenesis by chemokines. , 2004, Trends in cardiovascular medicine.

[17]  S. Schroeder,et al.  Effects of atorvastatin on in-stent stenosis in normo- and hypercholesterolemic rabbits. , 2003, International journal of cardiology.

[18]  Jilly F. Evans,et al.  Differential Leukotriene Receptor Expression and Calcium Responses in Endothelial Cells and Macrophages Indicate 5-Lipoxygenase–Dependent Circuits of Inflammation and Atherogenesis , 2003, Arteriosclerosis, thrombosis, and vascular biology.

[19]  T. Cohnert,et al.  Expanding expression of the 5-lipoxygenase pathway within the arterial wall during human atherogenesis , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[20]  C. Funk,et al.  Prostaglandins and leukotrienes: advances in eicosanoid biology. , 2001, Science.

[21]  J. Liao,et al.  Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors. , 2001, Arteriosclerosis, thrombosis, and vascular biology.

[22]  T. Saito,et al.  Functional characterization of cysteinyl leukotriene CysLT(2) receptor on human coronary artery smooth muscle cells. , 2001, Biochemical and biophysical research communications.

[23]  M. Bäck.  Studies of receptors and modulatory mechanisms in functional responses to cysteinyl-leukotrienes in smooth muscle. , 2001, Acta physiologica Scandinavica. Supplementum.

[24]  J. Egido,et al.  Atorvastatin reduces NF-kappaB activation and chemokine expression in vascular smooth muscle cells and mononuclear cells. , 1999, Atherosclerosis.

[25]  Y. L. Chen,et al.  Monocyte chemotactic protein-1 gene and protein expression in atherogenesis of hypercholesterolemic rabbits. , 1999, Atherosclerosis.

[26]  J. Egido,et al.  HMG-CoA reductase inhibition by atorvastatin reduces neointimal inflammation in a rabbit model of atherosclerosis. , 1998, Journal of the American College of Cardiology.

[27]  R. Ross,et al.  Atherosclerosis is an inflammatory disease. , 1998, American heart journal.

[28]  E. Donetti,et al.  Proapoptotic effect of atorvastatin on stimulated rabbit smooth muscle cells. , 1997, Pharmacological research.

[29]  S. Dahlén,et al.  Leukotrienes and lipoxins: structures, biosynthesis, and biological effects. , 1987, Science.

[30]  P. Pajukanta,et al.  Genetics of atherosclerosis. , 2004, Annual review of genomics and human genetics.